What Has Been The Evolution of the Ischemic Heart Disease IHD Drugs Market in Recent Years?
The ischemic heart disease ihd drugs market has seen considerable growth due to a variety of factors.
• The market for drugs treating ischemic heart disease (IHD) has experienced significant growth in recent times. The market which stands at $6.36 billion in 2024 is projected to reach $6.71 billion in 2025 with a compound annual growth rate (CAGR) of 5.6%.
This past growth has occurred due to factors such as the increasing global incidents of ischemic heart disease, better awareness and diagnostics, changes in lifestyle and dietary habits, government policies supporting cardiovascular health, collaborations to conduct clinical trials, and insurance coverage and reimbursement policies.
How Will the Ischemic Heart Disease IHD Drugs Market?
The ischemic heart disease ihd drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for drugs used in the treatment of ischemic heart disease (IHD) is predicted to experience constant growth in the upcoming years. It is forecasted to reach $7.86 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.0%.
The forecast period's growth can be ascribed to factors such as the increasing age of the population, tailored medicine strategies, focus on cardiovascular prevention, worldwide healthcare policies and ventures, and global research partnerships. Key trends projected for this period incorporate a shift towards precision medicine methods, a concentrated effort on new anti-atherogenic agents, advancements in the domain of lipid-reducing therapies, the incorporation of anti-inflammatory agents, as well as the evolution of antithrombotic and antiplatelet drugs.
Which Factors Are Boosting Growth In The Ischemic Heart Disease IHD Drugs Market?
The Ischemic Heart Disease (IHD) drugs market is anticipated to grow due to the rising prevalence of obesity and diabetes worldwide. Diabetes, a sustained metabolic disorder, elevates blood glucose levels, while obesity engenders an excess buildup of body fat, which can cause various health issues. IHD drugs are commonly prescribed to obese and diabetic individuals to control cardiovascular risk factors including hypertension and dyslipidemia, reducing the likelihood of ischemic heart disease. For example, the UK-based World Obesity Federation reported in 2022 that by 2030, one billion people globally, encompassing 1 in 5 women and 1 in 7 men, will be obese. The National Health Service, another UK-based government department, announced in June 2024 that in 2023, over half a million (549,000) additional individuals were at risk of type 2 diabetes, elevating the total number of those with pre-diabetes registered with a GP to 3,615,330. This is a considerable rise compared to 3,065,825 in 2022, marking a nearly 20% increase. This growing prevalence of diabetes and obesity thus facilitates the expansion of the Ischemic Heart Disease drugs market. The projected surge in heart failure cases is another impelling factor for the growth of the Ischemic Heart Disease (IHD) drugs market. Heart failure, a persistent condition in which the heart cannot sufficiently pump blood to satisfy the body's necessities for blood and oxygen, is the root cause of fatigue, breathing difficulty, and performance hindrance in daily activities. IHD drugs are pivotal in the treatment of heart failure, as they mitigate risk factors and symptoms, thus preventing heart failure. These medicaments curtail the heart's pacemaker activity and greatly benefit heart failure patients with decreased ejection fractions and elevated resting heart rates after tolerating a beta-blocker. In September 2023, according to the US-based Heart Failure Society of America, an estimated 6.7 million Americans aged over 20 years had heart failure, and the number is set to ascend to 8.5 million Americans by 2030. Consequently, the increasing rate of heart failure contributes significantly to the growth of the Ischemic Heart Disease drug market.
What Key Areas Define The Segmentation Of The Global Ischemic Heart Disease IHD Drugs Market?
The ischemic heart disease (IHD) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Pre-Book The Ischemic Heart Disease IHD Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Ischemic Heart Disease IHD Drugs Market?
Leading firms in the ischemic heart disease (IHD) drugs market, such as Bristol Myers Squibb, are striving to develop cutting-edge myosin inhibitors, aiming to secure a competitive advantage in the market. Myosin inhibitors are beneficial for conditions like hypertrophic cardiomyopathy (HCM) since these drugs lessen myosin activity in the heart muscle, thereby diminishing contraction force. These drugs are especially needed when the heart muscle becomes excessively thick and affects heart functioning. For instance, in April 2022, the US-based pharmaceutical company, Bristol Myers Squibb, introduced Camzyos (mavacamten). This new drug, the first of its kind as a cardiac myosin inhibitor, is authorized for the treatment of adults showing symptoms of new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM). Camzyos proves effective in enhancing functional capacity and symptoms by acting as an allosteric and reversible inhibitor selective for cardiac myosin. This action serves to mitigate hypercontractility and left ventricular hypertrophy while bettering cardiac filling pressures, helping to alleviate dynamic left ventricular outflow tract (LVOT) obstruction.
Who Are the Key Players In The Ischemic Heart Disease IHD Drugs Market?
Major companies operating in the ischemic heart disease (ihd) drugs market report are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GSK PLC
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz Inc.
• Sun Pharmaceutical Industries Limited
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Lupin Limited
• Recordati S.p.A.
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Ltd.
• Aurobindo Pharma Limited
• Alembic Pharmaceuticals Ltd.
• Eagle Pharmaceuticals Inc.
• Accord Healthcare Limited
• Macleods Pharmaceuticals Ltd.
• WG Critical Care LLC
• Novitium Pharma LLC
What Is The Most Dominant Region In The Ischemic Heart Disease IHD Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
